Welcome to nudaPETides. Coming soon.

The prescribing platform for veterinary peptide medicine. For licensed veterinarians.

Formulary
MusculoskeletalDogTier B

TB-500

Thymosin beta-4 fragment. Soft tissue and ligament repair. Sport and working animal recovery.

Weight

4,963 Da

Half-life

2 to 3 hours

Chain

43 amino acids

Studies

20 referenced. Latest 2023.

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library. Request access.

Overview

TB-500 is the active fragment of thymosin beta-4. Actin-binding regenerative peptide. Extensive equine sports medicine use. Cardiovascular repair literature. Corneal wound healing data.

The mobility and repair peptide. The one every equine sports medicine vet already knows.

Mechanism of action

  1. 01Binds G-actin and regulates cytoskeletal dynamics.
  2. 02Drives cell migration, angiogenesis, and endothelial repair.
  3. 03Suppresses inflammation via NF-kB pathway modulation.
  4. 04Mobilizes stem and progenitor cells to injury sites.
  5. 05Enhances corneal, cardiac, and dermal wound healing.

Molecular data

PropertyValue
Molecular weight4,963 Da
Chain length43 amino acids
TypeActin-sequestering peptide fragment
RouteSubcutaneous or intramuscular

Species applicability

Dog

Preclinical wound healing and cardiac ischemia data. Direct canine trials limited. Increasingly used in canine sports medicine for chronic soft tissue injury.

Horse

Established equine sports medicine peptide. Chronic tendon and ligament injury. Post-race and post-competition recovery.

Prescribing indications

MusculoskeletalMOST EFFECTIVE

Chronic tendon and ligament injury.

RecoveryEFFECTIVE

Post-orthopedic surgery recovery.

DermatologicEFFECTIVE

Non-healing wounds.

OphthalmicEMERGING

Corneal ulceration adjunct.

Dosing framework

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library.

Request access

Reconstitution and administration

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library.

Request access

Interactions

BPC-157 + TB-500SYNERGISTICSee Wolverine blend.
GHK-Cu + TB-500SYNERGISTICSee GLOW blend.

What to expect

Week 1 to 2Reduced pain and heat at injury site.
Week 2 to 4Improved range of motion. Reduced lameness scores.
Week 4 to 8Return to prior activity level in many cases.

Research library

Goldstein AL et al. Thymosin beta-4: multi-functional regenerative peptide. Expert Opinion on Biological Therapy.PubMedSosne G et al. Thymosin beta-4 promotes corneal wound healing. Experimental Eye Research.PubMedBock-Marquette I et al. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac repair. Nature.NatureMalinda KM et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology.PubMed

Related peptides

BPC-157

Recovery

View

Wolverine

Blend. Recovery.

View

GHK-Cu

Dermatologic

View

Regulatory footing

This monograph describes a compounded veterinary medication available by prescription only through a licensed veterinarian inside an active veterinarian-client-patient relationship. Not FDA-approved for animal or human use. Compounded on a patient-specific basis under FDA Guidance for Industry #256. For educational use by licensed veterinarians. Not intended for consumer self-prescribing.

For licensed veterinarians only. Compounded under FDA GFI 256. Not FDA-approved.